Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$21.17 USD
-0.36 (-1.67%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $21.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NTLA 21.17 -0.36(-1.67%)
Will NTLA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NTLA
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?
Other News for NTLA
First Week of June 21st Options Trading For Intellia Therapeutics (NTLA)
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Biotech Alert: Searches spiking for these stocks today
Intellia Therapeutics Welcomes New Principal Accounting Officer
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)